Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-01-26 Sale | 2023-01-27 4:42 pm | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 380,605 | $0.4132 | $157,266 | 541,905 (Direct) | View |
| 2022-04-19 Sale | 2022-04-20 4:25 pm | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 44,748 | $0.50219 | $22,472 | 922,510 (Direct) | View |
| 2021-05-20 Purchase | 2021-05-20 6:55 pm | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 20,547 | $3.6352 | $74,692 | 20,547 (Direct) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2024-01-12 Option Award | 2024-01-17 5:18 pm | N/A 2034-01-11 | Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D | 120,000 | $0 | 120,000 (Direct) | View |
| 2023-08-10 Option Award | 2023-08-14 4:24 pm | N/A 2033-08-09 | Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D | 225,000 | $0 | 225,000 (Direct) | View |
| 2023-06-12 Option Award | 2023-06-12 4:48 pm | N/A 2033-06-11 | Regulus Therapeutics Inc. | RGLS | Klassen Preston President & Head of R & D | 350,000 | $0 | 350,000 (Direct) | View |
| 2023-03-23 Option Award | 2023-03-24 12:35 pm | N/A N/A | Metacrine Inc. | MTCR | Klassen Preston Director | 842,211 | $0.47 | 1,384,116 (Direct) | View |
| 2023-03-23 Disposition | 2023-03-24 12:35 pm | N/A 2032-02-26 | Metacrine Inc. | MTCR | Klassen Preston Director | 842,211 | $0 | 1,384,116 (Direct) | View |
Ownership | 2023-03-21 7:35 pm | N/A 2033-03-15 | Zura Bio Ltd | ZURA | Klassen Preston President and COO | 0 | $0 | 476,756 (Direct) | View |
| 2022-04-14 Option Award | 2022-04-18 5:28 pm | N/A N/A | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 104,500 | $0 | 967,258 (Direct) | View |
| 2022-02-27 Option Award | 2022-03-01 4:56 pm | N/A 2032-02-26 | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 842,211 | $0 | 1,704,969 (Direct) | View |
| 2021-02-10 Option Award | 2021-02-12 5:03 pm | N/A 2031-02-09 | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 247,500 | $0 | 247,500 (Direct) | View |
Ownership | 2020-09-15 4:43 pm | N/A 2030-06-08 | Metacrine Inc. | MTCR | Klassen Preston President & CEO | 0 | $0 | 970,822 (Direct) | View |
| 2020-03-01 Option Award | 2020-03-03 6:15 pm | N/A 2027-03-01 | ARENA PHARMACEUTICALS INC | ARNA | Klassen Preston EVP and CMO | 70,000 | $0 | 70,000 (Direct) | View |
| 2019-10-14 Exercise | 2019-10-16 8:20 pm | N/A 2022-01-03 | ARENA PHARMACEUTICALS INC | ARNA | Klassen Preston EVP and CMO | 6,300 | $0 | 22,891 (Direct) | View |
| 2019-10-14 Tax Withholding | 2019-10-16 8:20 pm | N/A N/A | ARENA PHARMACEUTICALS INC | ARNA | Klassen Preston EVP and CMO | 2,309 | $47.32 | 22,891 (Direct) | View |
| 2019-06-27 Option Award | 2019-07-01 4:33 pm | N/A 2029-06-26 | Conatus Pharmaceuticals Inc. | CNAT | Klassen Preston Director | 20,000 | $0 | 20,000 (Direct) | View |